Citigroup Maintains Neutral on Insulet, Lowers Price Target to $165

Benzinga Newsdesk www.benzinga.com Negative 88.8%

Neg 88.8% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $175 to $165.